Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AmnioPul-02 in Hospitalized COVID-19 Patients
NCT05348772Phase 1Completed
- Sponsor
- Amniotics
- Start
- Oct 2022
- Primary completion
- Feb 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of PulmoStem in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Amniotics. Primary endpoint: Dose-limiting adverse events/toxicities at Day 7. Started Oct 2022; status: completed.
02
Drugs
PulmoStem
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05348772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05348772.